April 12, 2021
FDA: Class I recall of Medtronic’s Valiant Navion Thoracic Stent Graft System
Editor's Note
The Food & Drug Administration (FDA), on April 9, identified the recall of Medtronic’s Valiant Navion Thoracic Stent Graft System as Class I, the most serious.
The recall was initiated because of the risk of stent fractures and endoleak concerns. The system is used to repair lesions of the descending thoracic aorta.
There have been 11 reported issues, including two injuries and one death. Distribution dates were November 12, 2018 to February 10, 2021.
Read More >>
Free Daily News
- Study: Excessive nurse overtime, agency staffing harm patients
- Commentary: Technology no substitute for cadaver-based medical education
- Study: Early-stage breast cancer surgery may not be necessary after chemo, radiation
- Experimental brain implant translates thoughts to speech
- Nurses deem flexible, transparent scheduling key to satisfaction, retention
- OR Manager 2025 Career/Salary Survey offers opportunities to learn, give back
- The Joint Commission revises volume criteria for cardiac, stroke certifications
- Pulse oximetry monitoring at home found to save lives of high-risk opioid surgery patients
- New data suggest same-day discharge is safe for joint replacement patients with atrial fibrillation
- FBI investigates as Oracle health data breach exposes patient information
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement